Clinical Trials Logo

Clinical Trial Summary

Confirm the efficacy of the brexpiprazole QW formulation versus placebo for acute symptoms of schizophrenia


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05325645
Study type Interventional
Source Otsuka Pharmaceutical Co., Ltd.
Contact Drug Information Center
Phone +81-3-6361-7314
Status Recruiting
Phase Phase 3
Start date June 21, 2022
Completion date May 2025

See also
  Status Clinical Trial Phase
Completed NCT01668797 - Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia Phase 3
Completed NCT00350467 - A Randomized, Active-controlled, Double-blind, Parallel-Goup Study of the Efficacy and Safety of Extended Release(ER) Paliperidone in the Treatment of Schizophrenia Phase 3
Completed NCT03160521 - Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia Phase 3
Completed NCT01396421 - Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia Phase 3
Completed NCT01393613 - Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia Phase 3
Completed NCT00140166 - Treatment of Acute Schizophrenia With Vitamin Therapy Phase 4
Completed NCT01490086 - RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder Phase 2
Unknown status NCT00838032 - Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With Schizophrenia Phase 4